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Cell competition was originally described in Dro-
sophila as a process for selection of the fittest cells.
It is likely to play an important role in tissue homeo-
stasis in all metazoans, but little is known about its
role and regulation in mammals. By using genetic
mosaic mouse models and bone marrow chimeras,
we describe here a form of cell competition that
selects for the least damaged cells. This competition
is controlled by p53 but is distinct from the classical
p53-mediated DNA damage response: it persists for
months, is specific to the hematopoietic stem and
progenitor cells, and depends on the relative rather
than absolute level of p53 in competing cells.
The competition appears to be mediated by a non-
cell-autonomous induction of growth arrest and
senescence-related gene expression in outcom-
peted cells with higher p53 activity. p53-mediated
cell competition of this type could potentially con-
tribute to the clonal expansion of incipient cancer
cells.
INTRODUCTION
Despite being genetically identical, cells in multicellular organ-
isms are unequal in many ways. Even developmentally equiva-
lent cells within a given tissue are heterogeneous because of
stochastic variation in gene expression (Bahar et al., 2006;
Chang et al., 2008; Spencer et al., 2009), or unequal exposure
to nutrients, oxygen, growth factors, and stress. Elimination of
stressed, damaged, or otherwise suboptimal cells is important
for tissue function and homeostasis. It can occur through
well-characterized cell-autonomous mechanisms that are trig-
gered based on the absolute degree of cell stress or damage.
For example, DNA damage that exceeds a certain level induces
p53-mediated apoptosis or cell cycle arrest. However, cell-
autonomousmechanisms that are based on the absolute degree
of damage may not be sufficient to ensure that the healthiest
cells available are those that are maintained for ongoing tissue
homeostasis. Thus, under certain conditions, cell fate may
depend on the relative status of other cells in the same tissue,
and cell-extrinsic mechanisms that depend on relative cell
fitness may exist to complement cell-autonomous mechanisms
that are based on the absolute level of fitness (Figure 1A).Active elimination of suboptimal cells by cell competition was
identified and subsequently well characterized in developing
Drosophila wing (Adachi-Yamada and O’Connor, 2004; de la
Cova et al., 2004; Morata and Ripoll, 1975; Moreno and Basler,
2004; Simpson and Morata, 1981). Cell competition has also
been described in a diverse range of model organisms and cell
types, such as Drosophila germline stem cells (Jin et al., 2008;
Rhiner et al., 2009; Sheng et al., 2009); somatic and germline
stem cells of different colonies of Botryllus (Laird et al., 2005);
and prestalk and prespore cells in Dictyostelium (Santorelli
et al., 2008). Cell competition is also likely to play an important
role in mammalian biology (Baker and Li, 2008; Khare and Shaul-
sky, 2006; Moreno, 2008; Raff, 1992), and several phenomena
described in mammals may potentially be the result of cell
competition (Oertel et al., 2006; Oliver et al., 2004; Rajewsky,
1996; Zhao and Reed, 2001).
It is not yet known whether the examples of cell competition
described so far share similar underlying mechanisms, or
whether multiple types of cell competition exist. Regardless of
mechanism, the defining feature of cell competition is that the
cell fate is dependent on the presence, within the same tissue
compartment, of developmentally equivalent cells with different
levels of fitness sharing a common limiting resource (such as
nutrients, growth or survival factors, or space). At the cell popu-
lation level, the outcome of cell competition is a greater contribu-
tion of cells with higher fitness to overall tissue composition.
A number of tumor-suppressor pathways have been impli-
cated in cell competition in Drosophila (Tyler et al., 2007).
To investigate whether tumor suppressor-based competition
mechanisms exist in mammals, we have created a mosaic
mouse model with different levels of p53 activity. With this
model, we characterize a form of cell competition that is induced
by stress and is mediated by p53. Interestingly, the function of
p53 in stress-induced competition is distinct from the classical
p53-mediated acute DNA damage response (DDR). Finally, we
find that p53-mediated competition in the hematopoietic system
occurs primarily in the stem and progenitor cell compartment.RESULTS
Hematopoietic Stem and Progenitor Cell Competition
Is Induced by DNA Damage
To examine the effect of stress on the competitive status of cells
in the hematopoietic system, we used bone marrow (BM)
chimeras in competitive repopulation assays. Ionizing radiation
(IR) was used as a source of stress, because of its quantita-
tive nature. To exclude direct proapoptotic effects of IR onCell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc. 309
Figure 1. Differential Levels of DNA
Damage Trigger HSPC Competition
(A) Model of stress-induced cell competition. Cells
with intermediate level of stress (gray) have growth
potential in noncompetitive conditions but are
underrepresented in the tissue in the presence of
undamaged cells (white). Cells with high level
of damage (black) may undergo senescence,
apoptosis, or necrosis, regardless of the presence
of competitors.
(B) Design of the experiment shown in (C), (D), and
(E). Total BM was isolated from CD45.2 WT or
p53+/ mice 4 days after exposure to 1 Gy of IR,
and either used as is or mixed with BM from
untreated mice carrying the CD45.1 congenic
marker roughly at a ratio of 9:1. 15 3 106 cells
were injected into lethally irradiated CD45.2 recip-
ients, and the rest was stained with antibodies
against CD45.1 and HSPC markers and analyzed
by FACS to determine the initial contribution of
HSPCs from the donors.
(C and D) Total HSPC numbers (C) and percent
chimerism (D) were determined in the BM of the
recipient mice 16 weeks later by staining for
CD45.1 and HSPC markers.
(E) Chimerism in the PB was measured every
2 weeks after transfer. Error bars represent SEM,
nR 4; *p% 0.05.
(F and G) Design (F) of the experiment shown in (G)
and Figures S1C–S1G. Untreatedmdm2+/ or WT
CD45.2 donor BM was used as is or mixed with
BM from untreated WT CD45.1 mice, and BM
transfer and analysis were performed as in (B)
8 weeks after transfer.
Error bars represent SEM, n R 4; *p % 0.05;
**p% 0.01; ***p% 0.001. See also Figure S1.
Cell Stem Cell
P53 Mediates Hematopoietic Stem Cell Competitioncompeting cells, mice were treated with a low dose of IR (1 Gy)
and their BM was harvested on day 4 after the treatment.
At this time, no more IR-induced apoptosis is observed in the
BM (Christophorou et al., 2005), and expression of DDR genes
in total BM as well as in progenitor cells returns to baseline (Fig-
ures S1A and S1B available online). The BM from 1 Gy-treated
mice was transferred into lethally irradiated recipient mice, either
alone or mixed with untreated competitor BM, with 90% of BM
cells being from irradiated donors and 10% from untreated
donors (Figure 1B). 16 weeks later, the percentage of hemato-
poietic stem and progenitor cells (HSPCs; defined as line-
agec-kit+Sca1+CD48CD150+ population) from the untreated
donors increased approximately 4-fold relative to their initial
10% in the injected cell mixture (Figure 1C, WT, day 0 versus310 Cell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc.110). The absolute number of HSPCs
at the time of analysis was similar in
chimeras with and without untreated
competitors (Figure 1D, left and central
bars), so any differences in the contribu-
tion of one donor must have occurred at
the expense of the other. In addition, the
untreated donors contributed more that
the expected 10% to the lymphoid and
myeloid lineages in the peripheral blood
(PB), mirroring the changes observedwith HSPCs (Figure 1E, open symbols). These results suggested
that hematopoietic cells from untreated donors outcompeted
cells from irradiated donors. This IR-induced competition pre-
sumably involved long-term repopulating stem cells, because it
affected multiple lineages as well as phenotypic HSCs as late
as16 weeks posttransplantation.
Relative Level of Damage in HSPCs Is Sensed by p53
We next asked whether IR-induced competition is caused by
a general loss of fitness in irradiated cells resulting from accumu-
lated damage, or whether it is mediated by a dedicated sensor of
stress. p53 is a central conductor of cellular stress responses
(Chumakov, 2007; Levine and Oren, 2009; Vousden and Prives,
2009). We hypothesized, therefore, that p53 activity may be
Figure 2. Design and Characterization of the Mosaic Mouse
Model to Study Cell Competition
(A) Schematic of the inducible mp53 knockin allele integrated into
Rosa26 locus.
(B) Thymocyte apoptosis was assayed in mice of the indicated geno-
types 20 hr after exposure to 5 Gy by propidium iodide (PI) exclusion
assay. The dye can penetrate only damaged cell membranes;
percentage of PI+ (dead) cells is shown. The data are representative
of two independent experiments, n = 2 in each.
(C) mp53 cell population size does not change in steady-state condi-
tions. Left: mosaicism in the PBL of the R26-mp53 CreER (solid lines)
and R26-eYFP CreER (dotted lines) at 15 weeks (left y axis) versus
HSPCs in the BM at 80 weeks (right y axis). Lines represent individual
animals. Right: comparison ofmosaicism levels in the PBLs at 5 weeks
of age (prebleed) and in the HSPC gate at 8 to 20 weeks of age. Here
and throughout the paper, fold change in GFPhi HSPCs is calculated
as follows: the percent of GFPhi HSPCs (analyzed at the end of the
experiment) is divided by percent of GFPhi PBLs in the prebleed
(analyzed at 5 weeks of age) of each mouse.
See also Figure S2.
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P53 Mediates Hematopoietic Stem Cell Competitiona measure of the stress-related competitive status of HSPCs.
If this is the case, then lowering p53 activity in irradiated HSPCs
should make them more resistant to being outcompeted.
We tested this possibility by using BM from irradiated p53+/
mice as competitors (Figure 1B). p53+/ rather than p53/ cells
were used because chimeras made with p53/ cells showed
signs of lymphoma and/or died by 7 weeks after transplantation.
16 weeks after transfer, HSPCs from the untreated donor
replaced a significant number of HSPCs of the irradiated (1 Gy)
wild-type (WT) donor, but not from irradiated p53+/ donor
mice (Figures 1C and 1D, right bar). Similar changes occurred
in the PB (Figure 1E, compare open versus closed symbols).
This result suggested that IR-induced competition depends on
the p53 level in the competing cells.
In contrast to the strong competitive advantage of irradiated
donor p53+/ cells (Figures 1C–1E), p53-deficient cells have
only modest competitive advantage in conventional BM repopu-
lation assays when donors are not irradiated (see below;
TeKippe et al., 2003). Thus, it is possible that p53-mediated
cell competition occurs only when p53 activity reaches certain
threshold level. To test this and to distinguish p53-mediated
cell competition from other effects of IR, we sought to use cells
that have elevated p53 activity in the absence of external gene-
toxic stress. The activity of p53 is highly sensitive to the level of
Mdm2 (Marine et al., 2006). mdm2+/ mice display enhanced
p53 responses to stress but have normal hematopoiesis (Men-
drysa et al., 2006). We made BM chimeras with unirradiated
WT and mdm2+/ (Montes de Oca Luna et al., 1995) donors
(Figure 1F). mdm2+/ BM showed no defect in reconstituting
the hematopoietic system of lethally irradiated recipients whenCelltransplanted alone (Figures 1G, 2nd bar; Figure S1C).
However, WT donor contribution to the HSPC pool
(Figure 1G, 3rd versus 4th bar; Figure S1D) and peripheral
organs (Figures S1C and S1F–S1G) was significantly
higher than expected in the presence of mdm2+/
competitor BM, but not in the presence of a littermate
WT competitor BM. Thus mdm2+/ HSPCs are outcom-
peted in vivo in the absence of external stress. This couldbe due either to increased background p53 activity in mdm2+/
HSPCs or to increased p53 activation by endogenous sources
of stress, or both.
Dominant-Negative Oncogenic Mutation of p53
Is Insufficient for Clonal Expansion In Vivo
To further characterize p53-mediated cell competition, we
created an inducible genetic mosaic mouse model. A targeting
construct driving expression of the oncogenic p53 mutant
R172H (mp53) together with GFP was knocked into the
Rosa26 locus, creating a mouse strain that we will refer to as
R26-mp53 (Figure 2A). The R172H mutant suppresses endoge-
nous p53 activity in a dominant-negative fashion by forming
mixed tetramers with wild-type p53, and thus reducing p53
binding to the p53-responsive element in its target genes
(de Vries et al., 2002; Willis et al., 2004). Transcription of the
mp53 and GFP in the transgene is controlled by the ubiqitous
b-actin and Rosa26 promoters but is blocked by a transcription
stop signal (Figure 2A). With Cre with either inducible activation
or variegated expression, the stop signal can be removed from
a fraction of cells in every tissue, producingmosaics of otherwise
equivalent cells in which GFP expression marks cells with lower
p53 activity resulting from coexpression of the dominant-nega-
tive mp53 (for more details see Supplemental Experimental
Procedures and Figure S2).
Correct targeting of the construct was confirmed by Southern
blotting (Figure S2A). In R26-mp53 mice that had the stop
cassette removed in all cells by germline recombination (R26-
mp53D mice), mp53 was moderately overexpressed (Fig-
ure S2B), with further accumulation upon DNA damage.Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc. 311
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P53 Mediates Hematopoietic Stem Cell CompetitionThymocytes inR26-mp53Dmice were protected from apoptosis
similar to p53/ controls (Figure 2B), consistent with data from
other mp53 mouse models (de Vries et al., 2002; Olive et al.,
2004), confirming that mp53 inhibited the endogenous p53
activity in these mice in the expected manner.
Primary cells expressing oncogenic p53 mutants in culture
divide faster and survive better than the WT controls (de Vries
et al., 2002; Lang et al., 2004; Olive et al., 2004). To test whether
mp53 cells have a growth advantage in vivo, we crossed R26-
mp53 mice to Cre-ER mice, in which Cre can be inducibly acti-
vated by tamoxifen injection (Badea et al., 2003). Because of
the low efficiency of Cre-mediated recombination in Cre-ER
mice, tamoxifen injection results in the generation of genetic
mosaics where only a fraction of cells has undergone recombi-
nation event. Administration of a single dose of tamoxifen to
R26-mp53; Cre-ER mice resulted in mosaic expression of
mp53 in the blood and other tissues, which could be monitored
through GFP expression (Figure S2C and data not shown). As a
control, we crossed Cre-ER mice to R26-eYFP reporter mice
(Srinivas et al., 2001) that do not expressmp53. Also, to generate
mp53 mosaicism by different means, we crossed the R26-mp53
mice to the Balancer-Cre strain, which expresses Cre in all
tissues and organs in a mosaic manner during early develop-
ment, because of stochastic activity of the Cre integration site
(Betz et al., 1996). Wemonitored the relative abundance of GFPhi
cells in the PB and HSPC compartment of the resulting R26-
mp53; CreER, R26-eYFP; CreER and R26-mp53; Balancer-Cre
strains. The percentage of GFPhi cells was nearly identical in
PB and HSPCs in all three strains (Figure 2C), and, because of
the stochastic nature of Cre activation in these strains, was
different in each mouse. The level of mosaicism was similar in
all hematopoietic lineages and progenitors of each individual
mouse (Figure 2C; Figure S2D) and remained constant up to
80 weeks (Figure 2C, left). Thus, in contrast to the in vitro obser-
vations (Olive et al., 2004; Willis et al., 2004), expression of mp53
under homeostatic conditions did not confer a selective advan-
tage in vivo, suggesting that the basal level of stress in vivo
does not create sufficient selective pressure (Marusyk and
DeGregori, 2008) to promote expansion of mp53 cells, at least
in the hematopoietic system.
DNA Damage Triggers p53-Dependent Cell
Competition in HSCs
We next examined the effect of DNA damage on p53-mediated
cell competition in the R26-mp53 mosaic mice. The mosaicism
was induced by tamoxifen injection into R26-mp53; CreER
mice. Five days later, initial levels of GFPhi cells were measured
in the PB (‘‘prebleed’’), andmice were treated with amild dose of
IR (2.5 Gy) (Figures 3A and 3B). After IR, the percentage of GFPhi
cells increased in myeloid and lymphoid lineages and in the
HSPC compartment (Figure 3B). The expansion of GFPhi cells
appeared to involve the long-term HSC pool, because a
20-fold increase in GFPhi cells persisted in the lymphoid and
myeloid PB lineages and linc-kit+Sca1+CD48CD150+ BM
compartment for at least 6months after a single 2.5 Gy treatment
(Figure 3B). Importantly, there was no significant difference in
total HSPC numbers between WT and mosaic mice 3 weeks
(Figure S3A) and 6 months (Figure S3B) after IR. Thus, rather
than simply expanding, the mp53 cells seemed to be replacing312 Cell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc.WT cells. This suggests that competition between mp53 and
WT HSPCs occurs within the constraints of the regulatory
circuits that normally control compartment size.
An increase in GFPhi differentiated cell subsets could reflect
either direct effects of p53 in differentiated cells or an increased
contribution of GFPhi HSPC pool to the differentiated cell com-
partment. To discriminate between these possibilities, we
made mice chimeric either in the entire hematopoietic system
(‘‘total’’ chimeras) or only within the lymphocyte compartment
(Figure 3C). For ‘‘total’’ chimeras, we transferred BM from
mosaic R26-mp53 donors into lethally irradiated recipients. To
achieve chimerism restricted to the lymphocyte compartment,
we transferred splenocytes from mosaic R26-mp53 donors
into Rag2/ hosts (Figure 3C). T and B cells transferred into
Rag2/ mice, which lack their own mature lymphocytes, can
stably reconstitute those populations (Sprent et al., 1991),
whereas other hematopoietic lineages and lymphocyte precur-
sors remain host derived.
Upon IR, the percent of GFPhi cells increased dramatically
both in the lymphocyte and HSPC compartments of the ‘‘total’’
chimeras (Figure 3D), whereas the numbers of GFPhi cells in
‘‘lymphocyte-only’’ chimeras did not change significantly (Fig-
ure 3E). Thus, our data suggest that IR-induced, p53-mediated
cell competition in the hematopoietic system occurs predomi-
nantly in the HSPC compartment.
p53-Mediated Cell Competition Is Distinct from Acute
p53-Mediated DNA Damage Response
In assays that measure the immediate consequences of IR, such
as growth arrest and apoptosis, lymphocytes are significantly
more radiosensitive than HSCs (Figure S3C; Anderson et al.,
1977; Down et al., 1995; Fujikawa et al., 2000; Kataoka and
Sado, 1975; Meijne et al., 1991; Ploemacher et al., 1992; van
Bekkum, 1991). At 2.5 Gy, these responses are strictly p53
dependent (Christophorou et al., 2005; Christophorou et al.,
2006). Strong competition among HSPCs but not lymphocytes
(Figures 3D and 3E) suggested that cell competition is distinct
from the acute p53-mediated DNA damage response (p53-
DDR). Consistent with that, the kinetics and dose response of
cell competition differed significantly from the classical p53-
DDR. Thus, in contrast to the p53-DDR, which has linear dose
dependence up to 5 Gy (Figure S3C; Down et al., 1995; Ploe-
macher et al., 1992), expansion of mp53 cells peaked at
2.5 Gy and was inhibited at doses of 5 Gy (Figure 3F) and higher
(data not shown). In addition, the kinetics of the cell competition
was inconsistent with the p53-DDR. By day 4 after IR, the time
when the acute p53 response has already ended (Figures S1A
and S1B; Christophorou et al., 2005, 2006), there was still no
significant change in the mp53:WT ratio within the HSPC com-
partment (Figure 3G; Figure S3D). The increase in mp53 HSPCs
was detectable on day 12 and continued progressively for at
least 2 months (Figure 3G).
To confirm that events relevant to cell competition occur after
the p53-DDR, we administered tamoxifen to induce recombina-
tion in R26-mp53; CreER mice either 2 days before or 7 days
after they had been irradiatedwith 2.5 Gy (Figure 3H). By 8weeks
after IR, the percent of HSPCs significantly increased in both
groups (in comparison to day 9 after IR and to untreated group)
(Figure 3I). Thus, IR-induced HSPC competition appears to be
Figure 3. Characterization of the p53-Medi-
ated Cell Competition
(A and B) Long-term effects of p53-mediated
competition. Mosaicism was induced in R26-
mp53; CreER mice by tamoxifen injection. 5 days
later, percentage GFPhi cells was determined in
the PB, and mice were treated with 2.5 Gy.
Percentage of GFPhi cells in PB subsets and in
HSPCs in the BM was assayed 200 days later.
(C–E) Cell type specificity of p53-mediated com-
petition. For (D), total BM fromR26-mp53;Mx1Cre
(please see Experimental Procedures for details)
mosaic mice was transferred into lethally irradi-
ated recipients (C, top schematic); for (E), total
splenocytes from R26-mp53; Mx1Cre mosaic
donors were transfered into Rag2/ recipients
(C, bottom schematic). After 1 month, half of the
chimeras in each group was subjected to 2.5 Gy.
Percentage of GFPhi cells was measured 1 month
after the 2.5 Gy treatment in HSPC compartment
of the BM chimeras (D) or in splenocyte subsets
of the lymphocyte-only chimeras (E).
(F) Effect of the IR dose on mp53 cell expansion.
Percentage of GFPhi cells was determined 1month
after exposure of R26-mp53 Balancer mosaic
mice to the indicated doses and normalized to
the prebleed.
(G) Kinetics of the mp53 cell expansion. R26-
mp53; CreER mosaic mice were analyzed at
indicated time points after exposure to 2.5 Gy.
(H and I) IR-induced HSPC competition can occur
after the acute DDR phase. R26-mp53; CreER
mice were injected with tamoxifen either 2 days
before (a) or 7 days after (b) 2.5 Gy exposure.
Unirradiated control mice (c) were injected with
tamoxifen at the same day as group (b). Shown
is ratio of GFPhi HSPCs (gated on lin-cKit+Sca-
1+CD48CD150+CD34 cells) at 8 weeks after IR
to the percent of GFPhi cells in the PB at day 9
after IR.
All data are representative of at least two indepen-
dent experiments, each with nR 3. Error bars re-
present SEM; *p% 0.05; **p% 0.01; ***p% 0.001.
Experiments in (F) and (G) were done with
both CreER and Balancer strains. See also
Figure S3.
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P53 Mediates Hematopoietic Stem Cell Competitionmediated by long-lasting changes in p53 activity distinct from
the acute DDR response.
p53-Mediated Cell Competition Depends on p53 Status
of the Competitors
If the increase in mp53 HSPCs were caused purely by protection
from apoptosis or growth arrest that are dependent on absolute,
not relative, levels of p53 activity, these cells would be expected
to always have the same advantage, regardless of what
percentage of the mp53 cells comprise of the total HSPC pool.
As a result, mp53 cell numbers would always increase to the
same extent upon IR. Instead, we found that the extent of
mp53 cell expansion was inversely proportional to the initial
number of mp53 cells (Figures 4A and 4B): that is, mp53 cells
expandedmuch more when they initially constituted only a small
minority. Our interpretation is that when mp53 cells are in
minority, they mostly compete with WT cells rather than witheach other. A similar phenomenon in population genetics, called
frequency-dependent selection, is mediated by competition
(Fitzpatrick et al., 2007).
We also found that the outcome of competition depended on
the relative p53 status of the competing cells. We created (mp53:
p53+/+), (mp53: p53+/), or (mp53: p53/) mixed BM chimeras,
and after reconstitution half of the animals were irradiated with
2.5 Gy. Four weeks later, contributions of the mp53 cells to
HSPC pool were compared to their preirradiation levels (Figures
4C and 4D). mp53 HSPCs expanded in the presence of p53+/+
(WT) competitors, did not change in the presence of p53+/
competitors, and contracted in the presence of p53/ compet-
itors (Figure 4D). This effect was only marginal in unirradiated
chimeras (Figure 4D).
As an independent means to probe the role of p53 in cell
competition, we performed a similar experiment but with p53+/
competitors carrying the congenic marker CD45.1 instead ofCell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc. 313
Figure 4. Stress Competition Is Not Cell
Autonomous
(A andB)mp53 cell expansion is frequency depen-
dent. Percentage of GFPhi cells was determined in
R26-mp53; Balancer mice 1 month after 2.5 Gy
exposure. Right y axis: percent of GFPhi HSPCs
(green squares). Left y axis: fold increase in GFPhi
HSPCs (blue triangles) and in GFPhi lineage-posi-
tive cells of the BM (red circles). Each number on
the x axis corresponds to percent GFPhi cells in
the prebleed of an individual mouse.
(C and D) Relative p53 status determines the
outcome of competition. p53+/+, p53+/, or p53/
BM was mixed with mosaic R26-mp53;Mx1Cre
BM. The mixtures were transferred into lethally
irradiated WT recipients. 1 month after the trans-
fer, percent of chimerism was determined in the
PB (prebleed), and half of the mice were treated
with 2.5 Gy. Percentage of GFPhi HSPCs was as-
sayed 1 month after the IR treatment and normal-
ized to the prebleed.
(E) The experiment was done as in (C) except that
p53+/ CD45.1 donor BM was used instead of
R26-mp53.
(F and G) Endogenous p53 is required for the
effects of mp53 on cell competition. Percentage
of GFPhi HSPCs were determined in R26-mp53
CreER mosaic mice crossed onto p53+/+, p53+/,
or p53/ background, 1 month after exposure
to 2.5 Gy, and normalized to prebleed.
All data are representative of at least two
independent experiments, each with n R 3.
Error bars represent SEM. *p% 0.05; **p% 0.01,
***p% 0.001.
Cell Stem Cell
P53 Mediates Hematopoietic Stem Cell CompetitionR26-mp53. CD45.1+; p53+/ HSPCs expanded in the presence
of the p53+/+ but not p53/ BM (Figure 4E), confirming the
observations obtained with the R26-mp53 mouse model.
Selective Advantage of mp53 Does Not Require
Gain-of-Function Properties
In addition to its dominant-negative effects, the R172H mutant
p53 used in this study can also contribute to tumorigenesis by
gain-of-function mechanisms (Lang et al., 2004; Weisz et al.,
2007). The effects of thismutant on cell competition could, there-
fore, be mediated either by suppressing endogenous p53 or
(at least in part) by interfering with the related proteins p63 and
p73 (Lang et al., 2004; Weisz et al., 2007). If a gain-of-function
mechanism contributes to mp53-mediated cell competition in
ourmousemodel,mp53-expressing cells should have a selective
advantage even in the absence of the endogenous WT p53.
However, when R26-mp53; CreER mice were crossed to a
p53-heterozygous background, the advantage of the mp53 cells
was decreased compared to the p53+/+ background; and on the
p53/ background, IR did not stimulate expansion of the mp53314 Cell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc.HSPCs at all (Figures 4F and 4G). Thus,
the extent of HSPC competition was
proportional to the ratio of the mutant
and endogenous p53.
Collectively, these data indicate that
in our experimental system, mp53increases cell’s competitive status through a dominant-negative
rather than a gain-of-function mechanism.
Apoptosis Does Not Contribute to p53-Mediated
HSPC Competition
InDrosophila, cells with higher levels of Myc induce apoptosis of
the neighboring cells (de la Cova et al., 2004; Moreno and
Basler, 2004). ‘‘Loser’’ cells, otherwise lost from the tissue,
can be retained by increased dosage of the antiapoptotic gene
dIAP1 (Moreno and Basler, 2004) or decreased dosage of the
proapoptotic gene hid (de la Cova et al., 2004). To test whether
blocking apoptosis can protect loser HSPCs from p53-depen-
dent stress-induced competition, we crossed R26-mp53;
CreER mice to Hk-Bcl-2 transgenic mice, which overexpress
Bcl2 in the entire hematopoietic system (Domen et al., 1998).
Bcl-2 expression in these mice protects HSCs from the cyto-
toxic effects of IR (Domen et al., 1998). Nevertheless, mp53-
expressing HSPCs were still able to expand in the R26-mp53;
CreER; Hk-Bcl-2 transgenic mosaic mice to the same extent
as in the transgene-negative littermates (Figures 5A and 5B),
Figure 5. Contribution of Proliferation and Apoptosis to p53-Mediated Competition
(A and B) Protection from IR-induced apoptosis by Bcl2 does not inhibit p53-mediated competition. R26-mp53 CreERmice were crossed to Hk-Bcl-2 transgene
(Bcl2) and compared to nontransgenic R26-mp53; CreER littermates (). Mice were treated and analyzed as in Figure 4F.
(C) HSPC proliferation is insufficient to induce p53-mediated competition. Percentage of GFPhi HSPCs were assayed in R26-mp53; CreER mosaic mice at
indicated times after treatment with 2.5 Gy IR or 3 mg 5-fluorouracil (5-FU), and normalized to prebleed.
(D and E) HSPCs were sorted fromWT,R26-mp53D, orR26-mp53mosaic mice 3 weeks after 2.5 Gy exposure. mRNAwas amplified and analyzed bymicroarray
(not shown) and qPCR (E).
All data are representative of at least two independent experiments, each with nR 3. Error bars represent SEM. *p% 0.05; **p% 0.01; ***p% 0.001. See also
Figure S4.
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killing of outcompeted cells.
To obtain further insight into the mechanism of p53-mediated
competition, we performed a microarray analysis comparing
genes expressed in WT and mp53 HSPCs under competitive
(mosaic mice) or noncompetitive (nonmosaic mice) conditions,
either untreated or 3 weeks after 2.5 Gy exposure (Figure S4A).
Selected genes were further analyzed by qRT-PCR. We found
that expression of apoptosis-related genes did not corre-
late with the cells’ competitive status (Figure S4B; and data
not shown), providing additional evidence that apoptosis is
unlikely to play a major role in IR-induced p53-mediated HSPC
competition.IR Triggers Differential Proliferation of ‘‘Winner’’
and ‘‘Loser’’ HSPCs
IR affects HSPC proliferation in two opposite ways: first, it
directly induces DNA damage-dependent transient cell cycle
arrest or long-term senescence; and second, by killing
peripheral cells it indirectly promotes HSPC compensatory
proliferation.
We first investigated the possibility that a massive entry of
normally quiescent HSCs into the cell cycle could bring about
intrinsic differences in proliferation rates between WT and
mp53 HSPCs. To test this, we treated R26-mp53; CreERmosaic
mice with 5-fluorouracil (5-FU) and measured changes in GFPhi
HSPC proportion. Unlike IR, which affects both PB leukocytesCell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc. 315
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progenitor cells but has no direct toxic effects on HSCs (Hodg-
son and Bradley, 1984; Randall and Weissman, 1997). Instead,
HSCs undergo robust proliferation in order to replenish the
killed cells, which peaks at day 5 and decreases to baseline by
day 12 after 5-FU treatment (Randall and Weissman, 1997).
The percentage of GFPhi HSPCs did not increase in R26-
mp53;Cre-ER mosaic mice by day 12 of 5-FU treatment (Fig-
ure 5C), whereas it increased 3-fold by the same time point after
IR (Figures 5C and 3G). Thus, even though overall recovery of
hematopoiesis from 5-FU treatment is affected by p53 status
(Wlodarski et al., 1998), our data indicate that stimulation of
HSPC proliferation is insufficient to promote p53-mediated
competition.
Consistent with this, p53-deficient cells show only a modest
advantage in mixed BM chimeras in the absence of IR (Figures
4D and 4E; TeKippe et al., 2003), and mp53 cells in R26-
mp53;Cre-ER mosaic mice did not expand for up to 80 weeks
(Figure 3F). Repopulation of BM chimeras and long-term homeo-
static maintenance of hematopoiesis in mosaic mice both
require many HSC divisions, so any differences in proliferation
rates should have been apparent. Together, these data suggest
that, unlike in cultures of MEFs (Olive et al., 2004) and cell lines
(Willis et al., 2004), expression of mp53 does not alter prolifera-
tion of HSPCs in vivo in the absence of DNA damage.
However, we observed a proliferation-related ‘‘signature’’
when comparing the gene expression profiles of WT and mp53
HSPCs after IR via microarrays (data not shown) followed by
qPCR (Figures 5D and 5E). Several positive markers of cell prolif-
eration, such as Ki67, cyclin B1, cyclin A2, and ribonucleotide
reductase subunit Rrm2, were all expressed at higher levels in
mp53 than in WT cells sorted by flow cytometry from irradiated
mosaic mice (Figure 5E, compare columns 2 versus 4). Genes
encoding negative regulators of HSC proliferation, p57kip and
necdin, displayed the opposite pattern of expression (Fig-
ure 5E). Importantly, these changes in gene expression were
dependent on the presence of competitor cells: expression of
these genes differed between cells of the same genotype but
isolated from mosaic versus nonmosaic irradiated mice
(Figure 5E, compare columns 1 versus 2 and 3 versus 4). These
data suggest that one of the mechanisms underlying p53-medi-
ated HSPC competition is a non-cell-autonomous effect of p53
on cell proliferation.
Senescence-like Phenotype in Outcompeted HSPCs
The slow kinetics of p53-mediated competition (Figure 3G) sug-
gested that a single dose of IR induced long-term changes
in HSPCs that affected their competitive status. Competitor-
dependent changes in the expression of cell cycle-related genes
observed 3 weeks after IR (Figure 5E) provided further evidence
that DNA damage had a prolonged, p53-dependent effect on
HSPC proliferation reminiscent of senescence. p53 has been
implicated in stress-induced senescence (Itahana et al., 2001),
and IR selectively induces senescence in HSCs (Wang et al.,
2006).We therefore analyzed expression of senescencemarkers
in competing HSPCs.
p16INK4a is amarker andmediator of HSC senescence (Janzen
et al., 2006; Sharpless and DePinho, 2007). Based on qRT-PCR
analysis, expression of p16 was changed during IR-induced316 Cell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc.competition in a way that reflected differences in p53 activity
(Figures 6A and 6B). Furthermore, expression of Ezh2 (Tang
et al., 2004), a Polycomb group gene implicated in senescence
(Bracken et al., 2007; Kamminga et al., 2006), control of cdkn2a
locus (Bracken et al., 2007), and HSC exhaustion (Kamminga
et al., 2006), was increased in winner and decreased in loser
HSPCs. In addition, P-selectin and Sdpr, which are upregulated
in aged HSCs (Chambers et al., 2007; Rossi et al., 2005), were
also upregulated in loser and downregulated in winner HSPC
cells (Figure 6B). IRF-8 is downregulated both in human and
mouse HSCs with age (Stirewalt et al., 2009); it was upregulated
in winner and downregulated in loser HSPCs (Figure 6B).
Importantly, similar to proliferation-related genes discussed
above, these changes occurred in cells of the same genotype
in a way that depended on the presence of the competitor cells
(Figure 6B, compare columns 1 versus 2 and 3 versus 4).
Senescence of HSCs is, at least in part, dependent on p16
(Janzen et al., 2006). We therefore used cdkn2a knockout mice
(lacking both p16INK4a and p19Arf) as a ‘‘senescent-deficient’’
mouse model to test whether IR-induced HSPC competition
depends on p16-mediated senescence. To this end, we made
BM chimeras by using R26-mp53 cells mixed with either
cdkn2a+/+ or cdkn2a/ cells (Figure 6C) and compared the
ability of mp53 HSPCs to expand after IR. p16/ HSCs from
young mice (Janzen et al., 2006) as well as cdkn2a/ mice
(Figure S5A) do not have an advantage in competitive reconstitu-
tion assays. Nonetheless, in the presence of cdkn2a/ compet-
itors, the contribution of mp53 donor cells to the HSPC pool was
decreased, both with and without IR (Figure 6D). These changes
did not affect the frequency or total HSPC number in the BM
(Figure S5B and data not shown). A similar experiment with
cdkn2a/ and p53+/ mixed bone marrow chimeras produced
analogous results (Figure 6E). Collectively, these data suggest
that p53-mediated IR-induced competition proceeds through
induction of senescence-like state in the outcompeted HSPCs.
Genes Involved in Cell Interactions
with the Environment Are Differentially
Expressed in Competing HSPCs
A large group of genes differentially expressed in competitive
versus noncompetitive conditions encoded proteins that medi-
ate cell interactions with the environment. This group included
proteins involved in HSC adhesion and migration (P-selectin,
Robo4, L-selectin) (Figures 6B and 7A) and in modulation of
receptor signaling (CD44, TGFbRIII [betaglycan], and SOCS2)
(Figure 7A).
Mobilization of HSCs to PB and spleen is induced by variety
of treatments, including cytotoxic drugs. It is possible that IR
induced mp53 HSC expansion by increasing their ‘‘affinity’’ for
some of the several currently recognized sites of HSC residence
(Papayannopoulou and Scadden, 2008). To investigate whether
the expansion occurred preferentially at one site, we followed
changes in GFPhi HSPCs in BM and spleen after IR. Although
with different kinetics, mp53 HSPCs increased at both sites at
4 and 21 days after IR (Figure S6). Thus, although differential
homing may contribute to competitive advantage of p53 HSPCs
(for example, the availability of mitogens or self-renewal factors
may vary across different niches), relocation to the spleen cannot
account for overall mp53 cell expansion.
Figure 6. Senescence Is Implicated in IR-Induced Competition
(A and B) Expression of senescence marker genes was measured by qPCR as in Figure 5D.
(C–E) WT or cdkn2a/ BM was mixed with either p53+/ BM (D) or R26-mp53 mosaic BM (E) and transfered into lethally irradiated WT recipients. Mice were
treated and analyzed as in Figures 4C–4E.
All data are representative of two independent experiments, each with nR 3. Error bars represent SEM. *p% 0.05; **p% 0.01; ***p% 0.001. See also Figure S5.
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Cell competition has been implicated in tissue development
and homeostasis in several model organisms (Johnston, 2009).
Here, we describe a form of cell competition in the mammalian
hematopoietic system that appears to be based on the different
levels of stress accrued in individual cells within a population.
This stress-induced competition is mediated by p53, and at
least in the hematopoietic system, it is restricted to the HSPC
compartment where outcompeted cells appear to acquire a
senescence-like phenotype. p53 is known to function as a sen-
sor for multiple forms of cell stress and DNA damage, and
because p53 activity is a graded function, it is well suited for
reporting on different relative levels of cellular stress or damage.
Although both DDR and stress-induced competition are
mediated by p53, our data suggest that they are separate
phenomena. Classical p53-mediated DDR is a cell-autonomous
process that is triggered based on the absolute level of DNAdamage. In contrast, p53-mediated cell competition is based
on the relative level of cell stress or DNA damage and on the
presence of competitor cells. In addition, the p53-DDR and
stress-induced competition differ in other ways: the dose sensi-
tivity and timing of stress-induced competition are distinct from
the p53-DDR (for timing, compare Figures 3G and 3I to Figures
S1A and S1B; for dose sensitivity, compare Figure 3F to Fig-
ure S3C). Furthermore, p53 function in stress-induced competi-
tion is predominant in HSPCs (Figures 3D and 3E), whereas p53-
DDR (cell cycle arrest and apoptosis) in the hematopoietic
system is much more pronounced in differentiated cells such
as lymphocytes (Figure S3C; Anderson et al., 1977; Down
et al., 1995; Fujikawa et al., 2000; Kataoka and Sado, 1975;
Meijne et al., 1991; Ploemacher et al., 1992). Stress-based cell
competition may be particularly relevant for stem cells, which
contribute to differentiated cell pool and are long-lived to expe-
rience multiple insults. Recent evidence suggests that hemato-
poietic stem cells are inherently heterogeneous in terms of theirCell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc. 317
Figure 7. Two Categories of p53 Target Genes and Their Roles in Cell Behavior
(A) Adhesion and signal transduction-related genes differentially expressed in HSPCs under competitive versus noncompetitive conditions were assayed as
described in Figure 5D, with the addition of WT andmp53 HSPC sorted from unirradiated mosaicR26-mp53mice. All data are representative of two independent
experiments, each with nR 3. Error bars represent SEM. *p% 0.05; **p% 0.01; ***p% 0.001.
(B) p53 regulates expression of two classes of genes. Group A genes are targets of the canonical p53-DDR, which include DNA repair, cell cycle arrest, and cell-
intrinsic apoptosis. This group of genes affects cell fates such as proliferation versus cell cycle arrest and survival versus apoptosis, based on absolute levels of
p53 activity and regardless of the presence of competitor cells. Group B genes are involved in cell communication with the environment. Arrows indicate up- or
downregulation by p53; genes that were expressed in HSPCs in p53- and competition-dependent manner (in this study) are italicized.
(C) p53 can have two types of activities: when the level of damage or stress reaches a certain threshold, the cell can undergo p53-dependent apoptosis or cell
cycle arrest regardless of the status of other cells in the population. This effect is mediated by p53 target genes from group A. If the level of damage or stress is
below the threshold, the cells with lower level of p53 activity would outcompete cells with higher level of p53 activity. These competitive interactions are probably
mediated by p53 target genes from group B.
See also Figure S6.
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when identified by the most up-to-date assays (Schroeder,
2010). Our conclusion that p53-mediated competition involves
stem cells is based not only on stringent surface phenotype
but also on the long-term persistence (up to 6 months after IR;
Figure 3B) of the winners within multiple lineages and phenotypic
HSC pool. In addition, it is possible that competition affects less
primitive populations as well.
DNA damage is a type of stress that has important implications
for HSPC activity, as indicated by the fact that it is heritable,
often irreversible, and plays a central role in the decline of
stem cell function over time (Marusyk and DeGregori, 2008;
Nijnik et al., 2007; Reese et al., 2003; Rossi et al., 2007a; Sharp-
less and DePinho, 2007), probably resulting from both accumu-
lation of mutations (Marusyk and DeGregori, 2008) and con-
straints on cell proliferation (Rossi et al., 2007b).
How does p53 mediate stress-induced competition? In the
best-characterized case, in Drosophila wing development, cell
competition proceeds by killing of the neighboring cells (de la
Cova et al., 2004; Moreno and Basler, 2004). Based on this
evidence, it has been suggested that induction of death in
the neighboring cells is a definitive feature of cell competition
(Adachi-Yamada and O’Connor, 2004; Baker and Li, 2008; Mor-
ata and Martı´n, 2007). However, in other systems where cell
competition occurs, other outcomes may be more physiologi-
cally relevant than apoptosis, as is illustrated in recently found
cases of stem cell competition in theDrosophila germline (Issigo-
nis et al., 2009; Jin et al., 2008; Rhiner et al., 2009; Sheng et al.,
2009).
Consistent with this notion, during stress-induced competi-
tion, loser HSPCs underwent long-lasting senescence-like
changes, rather than apoptosis. Senescence induced in vitro is
characterized by permanent growth arrest and unresponsive-
ness to growth factors. However, this may be an extreme
case, whereas in vivo cells may experience different degrees
of senescence characterized by long-term growth inhibition.
For example, naturally aged HSCs display signs of senescence
while retaining the ability to proliferate (Rossi et al., 2007a).
We propose that p53-mediated stem cell-specific, senes-
cence-like response to DNA damage operates as a ‘‘memory
of past damage:’’ while still compatible with proliferation, it
permanently marks HSPCs that have experienced DNA damage
and thus promotes their gradual replacement by undamaged
cells over time, if such cells are available.
HSPCs with a given level of p53 activity either win or lose,
depending on p53 status of the competitor cells (Figures 4B–4E).
Moreover, the extent of winning depends on the ratio of the
competitors to one another (Figure 4B), which does not affect
the p53-DDR. This function of p53 is non-cell autonomous in
a sense that it depends on the relative p53 activity in competing
cells. It is likely to be based on p53-induced changes in expres-
sion of genes that control interactions of the cell with its environ-
ment (Figure 7B, ‘‘Group B’’ genes). Indeed, p53 regulates
expression of a number of growth factors, cytokines, and genes
involved in inflammation, cell adhesion, migration, and angio-
genesis (Levine et al., 2006; Menendez et al., 2009; Vousden
and Prives, 2009), which can impact the outcome of p53 activa-
tion. For example, regulation of expression of PAI-1 by p53 is
essential for p53-mediated senescence (Kortlever et al., 2006).More generally, a nonautonomous role of p53 has been demon-
strated in tumor-stroma interactions (Bar et al., 2010). However
in most cases, the role of p53-mediated control of ‘‘Group B’’
genes in normal physiology is not well understood. We found
that many genes in this category are expressed in a p53- and
competitor-dependent manner in HSPCs (Figure 7A), implicating
them in competitive interactions during stress response. Inter-
estingly, these genes were expressed much later than the clas-
sical p53-DDR targets. Their regulation by p53 is likely to have
distinct characteristics in terms of the dose and type of stress,
cell type specificity and kinetics, compared to the classical
p53-DDR targets. Because many p53-DDR target genes encode
basal components of apoptosis or cell cycle arrest, p53-DDR is
more relevant immediately upon exposure to high levels of
stress, because it will dominate over other events (Figure 7C).
However, if the level of stress is insufficient to trigger irreversible
cell cycle arrest or apoptosis, then graded activities of the
‘‘Group B’’ p53-regulated genes (Figure 7B) may influence cell
fate through competitive interactions with other cells.
Although selective expansion of HSCs with relatively lower
p53 activity is beneficial for optimal tissue composition and
therefore fitness, cells with p53 mutations can gain selective
advantage via the same mechanism. Because p53-mediated
competition occurs in long-lived HSCs, it may play an important
role in the early stages of cancer development. Furthermore,
because DNA damage levels increase with age (Sharpless and
DePinho, 2007), particularly in HSCs (Rossi et al., 2007a), p53-
mediated competition might also contribute to a sharp increase
in human cancer incidence with age (Armitage and Doll, 1954).
If so, minimizing exposure to conditions that create selective
pressure, increasing competitive status of normal cells, or other-
wise blocking unwanted cancer cell competition might provide
new possibilities for tumor suppression.
Multiple steps of acquisition of mutations in tumor suppres-
sors and oncogenes, each followed by clonal expansion, is a
widely accepted model of tumorigenesis, which is thought to
explain how rare and independent mutations can accumulate
in a single clone (Rangarajan et al., 2004). A physiological coun-
terpart of clonal expansion, if there is one, has not been charac-
terized. It is possible that both physiological and pathological
clonal expansion is mediated by cell competition. Thus, under-
standing mechanisms of cell competition in mammals may pro-
vide new insights into cancer initiation.EXPERIMENTAL PROCEDURES
Mouse Colony
Animals were maintained at the Yale Animal Resources Center. All animal
experiments were done with approval by the Institutional Animal Care and
Use Committee of Yale University. Rosa26-CreER, Balancer1, Mx1Cre,
p53/, and CD45.1 were from Jackson Laboratory; Rosa26-eYFP mice
were a kind gift of Dr. Frank Costantini; Hk-Bcl2mice were a kind gift of Dr. Irv-
ing Weissman; Mdm2+/ mice were a kind gift of Dr. Jean-Christoph Marine.
p53/ mice were crossed to CD45.1 strain for BM transfer experiments.
All mice used for BM transfers were on C57BL/6 background.Generation of R26-mp53 Mice
Mouse R172H p53 cDNAwas cloned into Rosa26 CAGGs vector (Sasaki et al.,
2006). Please see Supplemental Experimental Procedures for details.Cell Stem Cell 6, 309–322, April 2, 2010 ª2010 Elsevier Inc. 319
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Mice were irradiated with an X-Rad 320 at 3 Gy/min, or at a 137Cs source at
1.8 Gy/min. Mosaicism was induced in R26-mp53; CreER mice at 4 weeks
of age by a single intraperitoneal injection of 2 mg tamoxifen in peanut oil.
For BM transfers involving R26-mp53, interferon-inducible Mx1Cre mice
(Ku¨hn et al., 1995) crossed toR26-mp53were used. Depending on the desired
degree of mosaicism, mice were injected 1–3 times with 250 mg poly I:C (to
induce interferon response, and therefore activate Cre) at least 1 week before
use in BM transfers.
BM Transfer Experiments
One day before BM transfer, C57BL/6 recipients were irradiated with 10 Gy.
BM from donor mice was harvested and mixed, and 5 3 106 total cells was
transferred into the irradaited recipients by retroorbital vein injection.
In parallel, an aliquot of the mixed donor BM was analyzed by FACS to deter-
mine the ratio of the donors’ HSPCs. Four weeks after the transfer, PB was
stained with CD11b, CD45.1, and CD45.2 antibodies to determine the donors’
contribution before treatment (‘‘prebleed’’). At this time point, it correlated well
the original ratio of donors BM and also allowed to take into account variations
of individual mice. Where appropriate, mice where irradiated with 2.5 Gy the
same day. Donor contribution was determined by gating on GFPhi cells
(for experiments involving R26-mp53 donors) or CD45.1 and CD45.2 cells
(for all other experiments). For experiments in Figures 3, 4, and 6, the compe-
tition outcome (‘‘fold change’’) was determined based on the prebleed ratio.
For experiments on Figure 1 (because they did not involve irradiation of the
chimeras, there was no prebleed), ‘‘fold change’’ was calculated based on
the initial ratio of the donor’s HSPCs in the injected BM mix.
Quantification of Cell Competition
For R26-mp53mosaic mice, the quantification was done as follows. Because
at steady state the percent of the GFPhi lineagec-kit+Sca-1+CD48CD150+
cells was less than 1.5-fold different from the percent of GFPhi cells in the blood
of an individualmouse over several months, we used PBmosaicism at 5weeks
of age (‘‘prebleed’’) as a predictive value of the stem cell mosaicism in
untreated mice. For BM chimera experiments, prebleed was determined at
4 weeks after BM transfer. The outcome of cell competition (‘‘fold change in
HSPCs’’) was calculated as %GFPhi HSPCs (or %CD45.1+ cells in BM
chimeras) at the time of harvest divided by the %GFPhi in the prebleed.
Flow Cytometry
For HSPC staining, total BM cells were stained with antibodies against B220,
Gr1, CD3, CD4, CD8, Ter119, CD48, Sca1, c-kit (all from eBioscience or BD
PharMingen), and CD150 (BioLegend). Cells were analyzed by LSRII flow
cytometer. Unless otherwise indicated, HSPC cells were identified by gating
on lineagec-kit+Sca-1+CD48CD150+ cells. At least 300 cells were analyzed
per mouse. For FACS sorting, cells were stained as above, with the following
modifications: after staining with the lineage- and CD48-specific antibodies,
negative fraction was purified by autoMACS sorting, stained with the other
antibodies, and sorted on FACS Aria, FACS Vantage, or MoFlow into the lysis
buffer. Data were analyzed with FACS Diva software.
For thymocyte apoptosis, freshly isolated unfixed thymocytes were
analyzed in PBS containing propidium iodide.
Real-Time PCR
Total RNA was isolated from cells with Trizol (Invitrogen) and (in case of
HSPCs) amplified with RiboAmpHS kit from Arcturus. cDNA was synthesized
by SuperScriptIII (Roche) and random primers. Real-time PCR analysis was
performed with an Mx3000p (Stratagene) and SYBR green mix (Quantitect
from Quiagen). Relative amounts of mRNA were normalized to GADPH RNA
levels within each sample.
Data Analysis
All the statistical analyses were done by Student’s t test.
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A paper related to our study was recently published elsewhere (Marusyk et al.,
2010). The authors report that irradiation induced long-term expansion of p53-
deficient cells in BM chimeras, which can be blocked by addition of unirradi-
ated WT competitors. The selection within HSPC compartment occurs in the
absence of direct and immediate cytotoxicity.
